产品中心Cell Resources
联系我们CONTACT US
- 400-999-210024小时服务热线
BT-474 [BT474] (人乳腺导管癌细胞) (STR鉴定正确)
货号:CL-0040
规格:1×10⁶cells/T25培养瓶
价格: ¥1600
生长培养基:RPMI-1640+10μg/ml Insulin+2mM L-glutamine+20% FBS+1% P/S
产品概述
名称 | BT-474 [BT474] (人乳腺导管癌细胞) (STR鉴定正确) |
别称 | Bt-474; BT474 |
种属 | 人 |
生长特性 | 贴壁细胞 |
细胞形态 | 上皮细胞样 |
冻存条件 | 冻存液:55% 基础培养基+40%FBS+5%DMSO 温度:液氮 |
培养方案A(默认) |
培养条件:
气相:空气,95%;CO2,5%, 温度:37℃
|
推荐传代比例 | 1:2-1:4 |
推荐换液频率 | 2-3次/周 |
注意事项 | 1.BT-474细胞生长缓慢,细胞主要是成片生长;2.汇合至80%即可传代,细胞不会长太满,5-6天传代一次。 |
背景描述 | BT-474 [BT474]细胞是由E·Lasfargues和W·G·Coutinho从一个实心的乳腺浸润性导管癌中分离到的细胞株。 |
年龄(性别) | 女性;60岁 |
组织来源 | 乳腺导管癌 |
细胞类型 | 肿瘤细胞 |
肿瘤类型 | 乳腺癌细胞 |
生物安全等级 | BSL-1 |
倍增时间 | ~84-100 hours |
致瘤性 | Yes, in Amsterdam/IMR rats with regression in 10 days.Yes, in nude mice. |
保藏机构 | ATCC; CRL-7913ATCC; HTB-20 BCRC; 60359 BCRJ; 0353 DSMZ; ACC-64 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 10,11 D2S1338 19 D3S1358 17 D5S818 11,13 D7S820 9,12 D8S1179 10,12 D13S317 11 D16S539 9,11 D18S51 13,18 D19S433 14,17 D21S11 28,32.2 FGA 22,25 PentaD 9,14 PentaE 5 TH01 7 TPOX 8 vWA 15,16 D6S1043 12,17 D12S391 17,18 D2S441 10,14 -
STR鉴定图
参考文献
-
Development of a rare earth nanoprobe enables in vivo real-time detection of sentinel lymph node metastasis of breast cancer using NIR-IIb imaging(2023/08/04)
作者:Yuanyuan Zhu, Liang Song, Yongqu Zhang
期刊:CANCER RESEARCH
DOI:10.1158/0008-5472.CAN-22-3432
影响因子 :11.200
引用产品:CL-0007 CL-0040 CL-0041 CL-0149 CL-0211 CL-0228 CL-0525
-
Long-term cadmium exposure induces epithelial-mesenchymal transition in breast cancer cells by activating CYP1B1-mediated glutamine metabolic reprogramming in BT474 cells and MMTV-Erbb2 mice(2024/02/07)
作者:Jingdian Li, Peng Gao, Mingke Qin
期刊:SCIENCE OF THE TOTAL ENVIRONMENT
DOI:10.1016/j.scitotenv.2024.170773
影响因子 :9.800
引用产品:CL-0040
-
CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis(2023/06/09)
作者:Jiulong Ma, Chen Chen, Zhimin Fan
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2023.125295
影响因子 :8.200
-
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5(2024/03/11)
作者:Juan Li, Yu Liang, Shijie Zhou
期刊:BREAST CANCER RESEARCH
DOI:10.1186/s13058-024-01800-1
影响因子 :7.400
引用产品:CL-0040
-
A Novel Optical Fiber Terahertz Biosensor Based on Anti-Resonance for The Rapid and Nondestructive Detection of Tumor Cells(2023/10/23)
作者:Zhe He, Yueping Luo, Guorong Huang
期刊:Biosensors-Basel
影响因子 :5.400
引用产品:CL-0040
-
TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer(2020/10/08)
作者:Xiaoyi Xu, Wenjing Guo, Shihua Pan
期刊:Aging-US
影响因子 :5.200
引用产品:CL-0040
-
Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry(2024/05/08)
作者:Yu Ren, Luyi Feng, Zhihua Tan
期刊:Aging-US
影响因子 :5.200
引用产品:CL-0040
-
A comprehensive analysis of the role of QPRT in breast cancer(2023/09/18)
作者:Yiqing Yan, Lun Li, Zixin Wang
期刊:Scientific Reports
DOI:10.1038/s41598-023-42566-4
影响因子 :4.600
-
TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer(2023/12/18)
作者:Xiang Hu, Guangmei Li, Sisi Li
期刊:BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
DOI:10.1016/j.bbrc.2023.149388
影响因子 :3.100
引用产品:CL-0040
-
Analysis of TLR2 in Primary Endocrine Resistant of Breast Cancer(2024/02/22)
作者:Yunmei Wang, Guangxi Wang, Xiang Wang
期刊:Frontiers in Bioscience-Landmark
影响因子 :3.100
引用产品:CL-0040
-
Deciphering the map of METTL14-mediated lncRNA m6A modification at the transcriptome-wide level in breast cancer(2022/11/06)
作者:Dandan Yi, Fazhan Xu, Ru Wang, Chaoyu Jiang, Jiabo Qin, YiHsuan Lee, Xianbiao Shi, Jianfeng Sang
期刊:JOURNAL OF CLINICAL LABORATORY ANALYSIS
影响因子 :2.700
FAQs
Q:{{item.question}}
A:
产品资料
识别码示意图